title: Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
authors.affiliation: IBD Unit, St Mark's Hospital, Harrow, UK. philiphendy14@gmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Hendy
authors.forename: A
authors.initials: A
authors.lastname: Hart
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D000079424:Tumor Necrosis Factor Inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D000079424:Tumor Necrosis Factor Inhibitors; D000069285:Infliximab; D000068879:Adalimumab